Financial Analysis: Mereo BioPharma Group (NASDAQ:MREO) & Vertex Pharmaceuticals (NASDAQ:VRTX)

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) and Mereo BioPharma Group (NASDAQ:MREO – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.

Institutional and Insider Ownership

91.0% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 0.2% of Vertex Pharmaceuticals shares are held by insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Vertex Pharmaceuticals has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, Mereo BioPharma Group has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500.

Profitability

This table compares Vertex Pharmaceuticals and Mereo BioPharma Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vertex Pharmaceuticals 30.70% 21.98% 15.50%
Mereo BioPharma Group N/A -84.62% -71.44%

Earnings & Valuation

This table compares Vertex Pharmaceuticals and Mereo BioPharma Group”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vertex Pharmaceuticals $12.95 billion 10.53 $3.95 billion $15.54 34.61
Mereo BioPharma Group $500,000.00 97.41 -$41.88 million ($0.04) -7.62

Vertex Pharmaceuticals has higher revenue and earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Vertex Pharmaceuticals and Mereo BioPharma Group, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vertex Pharmaceuticals 0 2 25 1 2.96
Mereo BioPharma Group 2 3 3 0 2.12

Vertex Pharmaceuticals currently has a consensus price target of $596.44, suggesting a potential upside of 10.91%. Mereo BioPharma Group has a consensus price target of $1.67, suggesting a potential upside of 446.45%. Given Mereo BioPharma Group’s higher probable upside, analysts clearly believe Mereo BioPharma Group is more favorable than Vertex Pharmaceuticals.

Summary

Vertex Pharmaceuticals beats Mereo BioPharma Group on 11 of the 15 factors compared between the two stocks.

About Vertex Pharmaceuticals

(Get Free Report)

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.

About Mereo BioPharma Group

(Get Free Report)

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and cancer. Established in 2015 and based in the United Kingdom, the company advances drug candidates that it has acquired or licensed from other pharmaceutical developers. Its rare-disease programs include setrusumab, an investigational antibody being developed for osteogenesis imperfecta, and alvelestat, an investigational oral drug being studied for lung disease associated with alpha-1 antitrypsin deficiency.

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.